Cogent Biosciences (COGT) vs Edgewise Therapeutics (EWTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed Cogent Biosciences (COGT) over the past year, gaining 155.6% versus a gain of 93.1%. Over five years, COGT leads with a +225.5% price change compared with +121.1% for EWTX. Cogent Biosciences is the larger company by market cap ($5.22 billion vs $4.26 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | EWTX |
|---|---|---|
| Share price | $30.08 | $39.23 |
| Market cap | $5.22B | $4.26B |
| 1-day change | -0.20% | -0.86% |
| YTD return | -15.32% | +58.09% |
| 1-year return | +93.07% | +155.57% |
| 5-year return | +225.54% | +121.14% |
| EPS (TTM) | $-2.16 | $-1.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-328.94M | $-167.79M |
| 52-week high | $43.73 | $48.51 |
| 52-week low | $13.78 | $14.25 |
| Distance from 52-week high | -31.21% | -19.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +85.57% | +34.13% |
| Average volume | 1.90M | 1.34M |
| Shares outstanding | 173.52M | 108.60M |
| Employees | 258 | 127 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed COGT by 62.5 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Healthcare · Biotechnology · 258 employees
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Healthcare · Biotechnology · 127 employees
COGT vs EWTX FAQ
Which is bigger, Cogent Biosciences or Edgewise Therapeutics?
Cogent Biosciences (COGT) is larger, with a market capitalization of $5.22B compared with $4.26B for Edgewise Therapeutics (EWTX).
Which stock has performed better over the past year, COGT or EWTX?
EWTX returned +155.57% over the past 12 months, compared with +93.07% for COGT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Edgewise Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.